Published in Mol Genet Metab on May 03, 2009
Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G) | NCT02030015
Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality. J Inherit Metab Dis (2011) 0.99
Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis (2009) 0.91
Developing therapeutic approaches for metachromatic leukodystrophy. Drug Des Devel Ther (2013) 0.83
Corneal alterations during combined therapy with cyclodextrin/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease. PLoS One (2011) 0.76
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology (2007) 4.23
Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet (2007) 3.84
Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med (2007) 3.25
The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet Med (2011) 3.14
Pompe disease diagnosis and management guideline. Genet Med (2006) 3.03
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Paternal stress exposure alters sperm microRNA content and reprograms offspring HPA stress axis regulation. J Neurosci (2013) 2.52
The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab (2007) 2.23
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler (2013) 2.20
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. Am J Cardiovasc Drugs (2015) 2.19
Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol (2005) 2.16
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol (2011) 2.12
A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros (2012) 2.05
Genomic rearrangements resulting in PLP1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females. Am J Hum Genet (2002) 1.88
Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol (2010) 1.81
The NIH Undiagnosed Diseases Program: lessons learned. JAMA (2011) 1.79
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther (2003) 1.79
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet (2004) 1.66
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem (2007) 1.53
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol (2007) 1.52
The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics (2006) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Treatment of lysosomal storage disorders : progress with enzyme replacement therapy. Drugs (2007) 1.47
Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Hum Mutat (2002) 1.45
Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology (2013) 1.44
Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol (2009) 1.40
Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem (2009) 1.39
Hidden focal EEG seizures during prolonged suppressions and high-amplitude bursts in early infantile epileptic encephalopathy. Clin Neurophysiol (2005) 1.39
Epstein-Barr virus in pediatric multiple sclerosis. JAMA (2004) 1.38
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol (2004) 1.36
Sex-specificity in transgenerational epigenetic programming. Horm Behav (2010) 1.36
Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet (2002) 1.34
Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol (2012) 1.32
An evaluation framework for funding drugs for rare diseases. Value Health (2012) 1.31
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum (2007) 1.28
Analysis of DNA sequence variants detected by high-throughput sequencing. Hum Mutat (2012) 1.28
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol (2012) 1.21
O-GlcNAc transferase (OGT) as a placental biomarker of maternal stress and reprogramming of CNS gene transcription in development. Proc Natl Acad Sci U S A (2013) 1.21
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics (2006) 1.20
Lesion distribution in children with clinically isolated syndromes. Ann Neurol (2008) 1.17
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol (2013) 1.15
Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol (2009) 1.13
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol (2008) 1.12
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J Neuropathol Exp Neurol (2012) 1.12
An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat (2010) 1.11
Exome sequencing as a diagnostic tool in a case of undiagnosed juvenile-onset GM1-gangliosidosis. Neurology (2012) 1.11
Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev (2007) 1.08
Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis (2010) 1.08
Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology (2010) 1.07
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta (2010) 1.06
Clinical and genetic aspects of trigonocephaly: a study of 25 cases. Am J Med Genet A (2003) 1.06
Late onset Leigh syndrome and ataxia due to a T to C mutation at bp 9,185 of mitochondrial DNA. Am J Med Genet A (2007) 1.06
Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron (2013) 1.06
Pediatric multiple sclerosis. Neurologist (2010) 1.04
Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr (2010) 1.02
A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab (2008) 1.01
Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol (2011) 1.01
Genetic heterogeneity of syndromic X-linked recessive microphthalmia-anophthalmia: is Lenz microphthalmia a single disorder? Am J Med Genet (2002) 1.01
CDG-IL: an infant with a novel mutation in the ALG9 gene and additional phenotypic features. Am J Med Genet A (2005) 1.00
X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism. Mol Genet Metab (2011) 0.99
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol (2009) 0.98
Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab (2010) 0.98
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab (2007) 0.98
Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology (2014) 0.98
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother (2013) 0.97
GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta (2011) 0.97
Novel mutations in dihydrolipoamide dehydrogenase deficiency in two cousins with borderline-normal PDH complex activity. Am J Med Genet A (2006) 0.97
Natural history of infantile G(M2) gangliosidosis. Pediatrics (2011) 0.97
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet (2013) 0.96
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther (2006) 0.96
Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol (2006) 0.95
A validated disease severity scoring system for Fabry disease. Mol Genet Metab (2009) 0.95
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet (2003) 0.95
The management of multiple sclerosis in children: a European view. Mult Scler (2010) 0.95
The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease. Expert Opin Biol Ther (2009) 0.93
Mucolipidosis II presenting as severe neonatal hyperparathyroidism. Eur J Pediatr (2004) 0.93
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther (2002) 0.93
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther (2010) 0.93
Ornithine transcarbamoylase deficiency presenting with acute liver failure. J Inherit Metab Dis (2006) 0.92
An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper. Clin Chim Acta (2012) 0.90
Novel SNP array analysis and exome sequencing detect a homozygous exon 7 deletion of MEGF10 causing early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD). Neuromuscul Disord (2013) 0.90
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol (2013) 0.90
Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta (2010) 0.90
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica (2012) 0.89
Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delay. Am J Med Genet A (2008) 0.89
International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology (2013) 0.89
Pseudohallucinations after zolpidem intake: a case report. J Clin Psychopharmacol (2007) 0.89
Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol (2009) 0.89